ALK and chronic myelogenous leukemia, BCR-ABL1 positive: Identification of the gene fusions has been an essential part of charting the landscape of cancer genomic variations, deriving biomarkers for molecular diagnostics of cancer patients, and targeting therapies such as tyrosine kinase inhibitors for the treatment of kinase gene fusions such as BCR::ABL1 in CML patients (Cuellar et al. 2018) and EML4::ALK (Christopoulos et al. 2018) in lung cancer.